ETNB - Eli Lilly hurts NASH drug developers after mid-stage win for obesity therapy
2024-02-06 12:58:10 ET
More on Akero Therapeutics, 89bio, etc.
- Biotech And Pharma Diversification Pays Off
- Sagimet: Additional Upside Possible After Latest NASH Data Release
- Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play
- Karuna’s KarXT tops Evaluate’s most anticipated drug list
- Sagimet Biosciences prices public offering of 9M shares at $12.50 per share